Local Anesthetic: IQB-9392 has been developed as a new, potent and non-toxic amide local anesthetic derivative with some ability to cross human skin
Status: Preclinical Pharmacology and Toxicology in progress. Preliminary pharmacological and toxicological tests have shown that therapeutic index of IQB-9302 (i.e. activity/toxicity) is about 200% higher than other local anesthetics. In particular hemodynamic and electrophysiological studies in dogs have show that IQB-9302 is less cardiotoxic than bupivacaine.
Phase I clinical trials in progress. IQB-9302 has shown a longer duration of anesthetic effect than bupivacaine. More information concerning to IQB-9302 may be obtained here